Dipyridamole does not have any additive effect on the prevention of COVID-19 coagulopathy.

Sevgi Kalayoglu Besisik,Murat Ozbalak,Yavuz Burak Tor,Alpay Medetalibeyoglu,Murat Kose,Naci Senkal,Atahan Cagatay,Mustafa Erelel,Ahmet Gul,Figen Esen,Serap Simsek Yavuz,Haluk Eraksoy,Tufan Tukek

American journal of blood research（2022）

引用 0|浏览6

暂无评分

摘要

We think that our clinical experience is valuable in showing the real-life results of DP + LMWH treatment in COVID-19. This approach did not affect the coagulopathy rate. Our data did also not document an additive effect of DP in the COVID-19 outcome. Prospective controlled trials would give more convincing results regarding the role of DP in COVID-19 endothelial dysfunction and clinical outcome.

查看译文

关键词

COVID-19 pneumonia,SARS-CoV-2,coagulopathy,dipyridamole,low-molecular-weight heparin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要